Last updated on September 2017

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for participants with advanced/metastatic renal cell carcinoma (mRCC). The primary hypotheses of this study are: 1) The combination therapy of pembrolizumab plus axitinib is superior to sunitinib monotherapy with respect to Progression-Free Survival (PFS) as assessed by blinded independent central imaging review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and 2) the combination therapy of pembrolizumab plus axitinib is superior to sunitinib monotherapy with respect to Overall Survival (OS).

Clinical Study Identifier: NCT02853331

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Toll Free Number

Call for Information (Investigational Site 0092)
Tucson, AZ United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0086)
Orange, CA United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 8001)
Denver, CO United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0095)
Washington, D.C., United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0091)
Marietta, GA United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0078)
Chicago, IL United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0041)
Chicago, IL United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0035)
New Orleans, LA United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0046)
Lincoln, NE United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0088)
Buffalo, NY United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0032)
New York, NY United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0020)
Rochester, NY United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0087)
Charlotte, NC United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0009)
Cleveland, OH United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0037)
Portland, OR United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 8010)
Tualatin, OR United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0093)
Allentown, PA United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0013)
Philadelphia, PA United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0062)
Pittsburgh, PA United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 8004)
Charleston, SC United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0089)
Sioux Falls, SD United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0090)
Chattanooga, TN United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0070)
Germantown, TN United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0064)
Dallas, TX United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 8002)
Houston, TX United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 8003)
San Antonio, TX United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0072)
Salt Lake City, UT United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0082)
Fairfax, VA United States
  Connect »

MSD Online

MSD Brasil
Sao Paulo, Brazil
  Connect »

Thomas Johansson

MSD SRO Czech
Prague, Czechia
  Connect »

Dominique Blazy

MSD France
Paris, France
  Connect »

German Medical Information Center

MSD Sharp & Dohme GmbH
Haar, Germany
  Connect »

Szabolcs Barotfi

MSD Pharma Hungary Kft.
Budapest, Hungary
  Connect »

Colm Galligan

MSD Ireland (Human Health) Ltd.
Dublin, Ireland
  Connect »

Japan Call Center

MSD K.K.
Chiyoda-Ku, Tokyo, Japan
  Connect »

Jongho Ahn

MSD Korea LTD
Seoul, Korea, Republic of
  Connect »

Thomas Johansson

MSD Polska Sp. Z o.o.
Warsaw, Poland
  Connect »

Tatiana Serebriakova

Merck Sharp & Dohme IDEA, Inc.
Moscow, Russian Federation
  Connect »

Joaquin Mateos Chacon

Merck Sharp and Dohme de Espana S.A.
Madrid, Spain
  Connect »

I-Hua Su

Merck Sharp & Dohme (I.A.) Corp.
Taipei, Taiwan
  Connect »

Eran Gefen

MSD Ukraine LLC
Kiev, Ukraine
  Connect »

Mark Toms

Merck Sharp & Dohme Ltd.
Hoddesdon, United Kingdom
  Connect »